IPO activity in 2025 showed a marked rebound, led by the technology and healthcare sectors, after last year's sluggish performance. Aktis Oncology,
Everything you need to know about Aktis Oncology’s upcoming IPO
Categories
Biotechnology
Micron Q1 2026 earnings beat estimates; revenue surges 57%
Memory chipmaker Micron Technology Inc. (NASDAQ: MU) on Wednesday reported stronger-than-expected earnings for the first quarter of fiscal 2026. Revenue increased 57%
Pfizer affirms FY25 earnings guidance, provides full-year 2026 outlook
Pfizer Inc. (NYSE: PFE) has reaffirmed its earnings outlook for fiscal 2025 and revised revenue guidance. The pharma giant also initiated guidance
Unicycive is all-in on kidney care, focusing on underserved areas: CEO
Unicycive Therapeutics, Inc. (NASDAQ: UNCY) is a biotech firm engaged in the development of novel treatment options for patients with renal diseases.
Advantage of CERo’s CER receptor lies in native human protein-based antigen binding: CEO
CERo Therapeutics Holdings, Inc. is a biotechnology company pioneering engineered T cell immunotherapies to combat cancer, with a focus on hematologic malignancies
Viatris (VTRS) posts Q3 2025 results and updates 2025 guidance
Pharmaceuticals company Viatris Inc. (NASDAQ: VTRS) on Thursday reported financial results for the third quarter of fiscal 2025, and updated its outlook
ABBV Earnings: A snapshot of AbbVie’s Q3 2025 report
Pharmaceuticals company AbbVie, Inc. (NYSE: ABBV) on Friday reported a decline in earnings for the third quarter of fiscal 2025, despite an
BIIB Earnings: A snapshot of Biogen’s Q3 2025 results
Biotechnology firm Biogen Inc. (NASDAQ: BIIB) reported an increase in adjusted profit for the third quarter of 2025 when its revenues remained
Earnings Summary: A snapshot of Revvity’s (RVTY) Q3 2025 report
Revvity, Inc. (NYSE: RVTY), a provider of health science solutions and technologies, reported a decline in adjusted earnings for the third quarter
Infographic: How Thermo Fisher (TMO) performed in Q3 2025
Thermo Fisher Scientific Inc. (NYSE: TMO) reported its third quarter 2025 earnings results today. Revenue grew 5% year-over-year to $11.12 billion. Organic
Kairos Pharma’s goal is to intervene early in resistance and re-sensitize cancer cells to therapy: CEO
Kairos Pharma, Ltd. (NYSE: KAPA) is a biopharma company developing a pipeline of targeted therapies for cancer patients with high unmet medical
IPO News: MapLight Therapeutics targets $704 mln valuation in Nasdaq debut
In recent months, Wall Street has seen a surge of healthcare firms seeking to go public, as IPO activity continues to regain
Strategic partnerships have been essential to Profusa’s progress: CEO Ben Hwang
Profusa, Inc. (NASDAQ: PFSA) is a digital health company pioneering a new generation of biointegrated sensors. Its injectable biosensors are designed to
Eli Lilly (LLY) set to report Q2 2025 results. Here’s what to expect
Eli Lilly and Company (NYSE: LLY) had a positive start to fiscal 2025, reporting strong revenue and earnings growth for the first
BIIB Earnings: Highlights of Biogen’s Q2 2025 results
Biotechnology firm Biogen Inc. (NASDAQ: BIIB) on Thursday reported higher revenues and adjusted profit for the second quarter of 2025. The company
Bristol Myers Squibb (BMY) Earnings: 2Q25 Key Numbers
Bristol Myers Squibb (NYSE: BMY) reported its second quarter 2025 earnings results today. Total revenues inched up 1% year-over-year to $12.3 billion.
Plus Therapeutics CEO: Lead candidate REYOBIQ demonstrates strong safety and efficacy in early trials
Plus Therapeutics (NASDAQ: PSTV) is a pharmaceutical company engaged in the development of targeted radiotherapeutics for difficult-to-treat cancers. Currently, it is advancing
BIIB Earnings: Biogen Q1 2025 adj. profit drops despite higher revenues
Biotechnology firm Biogen Inc. (NASDAQ: BIIB) Thursday reported a year-over-year decrease in adjusted profit for the first quarter of 2025, despite an
Infographic: How Eli Lilly (LLY) performed in Q1 2025
Eli Lilly and Company (NYSE: LLY) reported its first quarter 2025 earnings results today. Worldwide revenue was $12.73 billion, up 45% compared
AbbVie Q1 2025 adjusted earnings increase on 8% revenue growth; beat estimates
Biopharmaceutical company AbbVie, Inc. (NYSE: ABBV) announced first-quarter 2025 financial results, reporting an increase in revenue and adjusted earnings. The company reported
Bristol-Myers Squibb swings to profit in Q1 2025; revenue drops
Bristol Myers Squibb (NYSE: BMY) reported net profit for the first quarter of 2025, compared to a loss last year. The biotechnology